Shortening TB Treatment With Optimised Rifampicin-Based Therapy and Disease Stratification: A Pragmatic Phase 3 Double-Blind Placebo-Controlled Randomised Trial (RIFAstrat)

RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease severity.

开始日期2026-02-01

申办/合作机构

Hamilton Health Sciences Corp.

[+2]

NCT07242781

/ Not yet recruiting临床1期

A Phase 1, Open-label, 2-part, Fixed-sequence, Crossover Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics of AR-LDD (BMS-986365) in Healthy Adult Male Participants

The purpose of this study is to evaluate the effect of Itraconazole and Rifampin on the drug levels of AR-LDD (BMS-986365) in healthy adult male participants.

开始日期2025-12-08

申办/合作机构

Celgene Corp.

CTR20254045

/ Active, not recruiting临床1期

一项在健康参与者中评价多剂量伊曲康唑或利福平或艾司奥美拉唑对单剂量TT-00420药代动力学影响的单中心、开放标签、固定序列、非随机、药物相互作用的I期临床研究

主要目的：评价多剂量伊曲康唑或利福平或艾司奥美拉唑在健康参与者中对单剂量TT-00420药代动力学（PK）的影响次要目的：评价TT-00420与伊曲康唑或利福平或艾司奥美拉唑在健康参与者中联合给药时的安全性和耐受性

开始日期2025-11-03

申办/合作机构

药捷安康（南京）科技股份有限公司

100 项与利福平相关的临床结果

登录后查看更多信息

100 项与利福平相关的转化医学

登录后查看更多信息

100 项与利福平相关的专利（医药）

登录后查看更多信息

35,353

项与利福平相关的文献（医药）

2026-02-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Machine learning approaches to predict drug resistance in tuberculosis

Article

作者: Subalakshmi, A T ; Mahesh, Arundhati

Tuberculosis (TB) remains a global health crisis, with 10.8 million cases and 1.25 million deaths in 2023. The rise of drug-resistant TB has complicated treatment, while traditional diagnostic methods face limitations in speed, cost, and accuracy. This study explores machine learning (ML) models to predict drug resistance from genomic variants, offering a faster and more comprehensive solution. We compiled a comprehensive dataset of variations and mutations associated with resistance phenotypes from databases such as TBDReaMDB, GMTV, WHO, and CARD. For each mutation, both sequence-based features (e.g., physicochemical property changes, Provean scores) and structure-based features (e.g., hydrophobicity, flexibility, accessible surface area) were derived. Ensemble ML models (Stacking, Bagging and Voting Classifiers) were evaluated for their ability to predict resistance to key anti-TB drugs: Fluoroquinolones, Rifampicin, Isoniazid, and Pyrazinamide. Results achieved indicated that the model behaved differently on six TB resistance genes (gyrA, gyrB, inhA, katG, rpoB, pncA), with accuracy varying from 66 % (gyrA Stacking) to 91.37% (pncA Voting) and ROC scores varying from 0.69 (gyrA Bagging) to 0.92 (pncA Stacking). The Bagging model performed best for gyrA, gyrB and rpoB with strong classification, while the Stacking classifier performed well for inhA. Voting classifier proved to be the top-performing classifier for katG and pncA gene. The top-performing model for both genes was chosen, emphasizing a gene-specific strategy to maximize resistance prediction. This study demonstrates that gene-specific ensemble models, supported by a comprehensive feature set, can provide valuable predictions of drug resistance in M. tuberculosis. While promising, the findings remain a proof-of-concept and require further validation on larger and more diverse clinical datasets before clinical application.

2026-02-01·VETERINARY RESEARCH COMMUNICATIONS

Acute pancreatic panniculitis in a domestic ferret (Mustela putorius furo): diagnostic insights and a potential drug-induced etiology

Article

作者: Gómez, Álex ; Giner, Jacobo ; Rodriguez-Largo, Ana ; Villanueva-Saz, Sergio ; Villora, José ; Juan-Sallés, Carles ; Marteles, Diana

Abstract:

Panniculitis is a rare condition in ferrets ( Mustela putorius furo ), previously linked to nutritional deficiencies, infections, trauma, and injections. Pancreatic panniculitis, caused by the systemic release of pancreatic enzymes during pancreatic injury, has been documented in humans and other animal species, but not in ferrets. This report describes the first known case in a domestic ferret. A 2-year-old male ferret presented with ulcerated cutaneous nodules predominantly affecting the hind limbs and inguinal abdominal region. The ferret had been treated with rifampicin and clarithromycin for suspected mycobacterial infection. Hyperglycemia, hyperglobulinemia, and elevated alkaline phosphatase were noted. Cytology and culture of the lesions revealed neutrophilic inflammation and Pseudomonas aeruginosa , respectively. The animal developed acute abdominal discomfort and died shortly after. Post-mortem examination revealed severe pancreatic necrosis and peripancreatic panniculitis, with splenic pyogranulomatous inflammation. Immunohistochemistry detected systemic coronavirus antigen (clone FCV3-70) only in the spleen. In this patient, prolonged use of rifampicin and clarithromycin is considered a potential contributing factor to the development of acute pancreatic necrosis. This case highlights the clinical relevance of pancreatic panniculitis in ferrets and suggests a possible association between extended rifampicin/clarithromycin therapy and pancreatic necrosis. Ultrasonography and serum glucose, lipase, and amylase measurements are recommended for early diagnosis. Histopathological evaluation remains essential for confirmation.

2026-02-01·JOURNAL OF ETHNOPHARMACOLOGY

Jieduquyuziyin prescription regulates the differentiation of Tfh cells in systemic lupus erythematosus through lysophosphatidyl ethanolamine metabolism

Article

作者: Yao, Xinyi ; Cao, Yi ; Zhao, Ting ; Wang, Yihan ; Ye, Keying ; Lin, Zhiting ; Wang, Xinchang ; Zhu, Xinchao ; Lu, Dingqi

ETHNOPHARMACOLOGICAL RELEVANCE:

The formula of Chinese herbal compound Jieduquyuziyin prescription (JP) can be used to treat systemic lupus erythematosus (SLE) and Its efficacy has been confirmed by clinical studies and has been approved for clinical treatment in China hospitals. The therapeutic mechanism of JP still needs further study, and this study focuses on its role in T cell differentiation and lipid metabolism regulation.

AIM OF THE STUDY:

To clarify the effects of JP on Tfh cell differentiation and explore the role of lysophosphatidyl ethanolamine (LPE) metabolic pathway in it.

METHODS:

The chemical composition of JP decoction was analyzed by high performance liquid chromatography combined with mass spectrometry (HPLC-MS). MRL/lpr mice served as the SLE model. The therapeutic effect of JP on SLE and the inhibitory effect on T cell subsets were evaluated by histoopathology, immunofluorescence, flow cytometry analysis and enzyme-linked immunosorbent assay (ELISA). Meanwhile, lipid metabolomics and transcriptomics were combined to explore the potential molecules by which JP regulates Tfh cells through the LPE metabolic pathway, and were verified by primary cell polarization experiments in vitro. Finally, molecular docking was performed to identify the active components of JP and validate the binding stability between these components and the key target.

RESULTS:

JP significantly alleviated kidney damage, reduced expression of autoantibodies and inflammatory factors, reduced the proportion of Tfh cells, and regulated the glycerol phospholipid metabolic pathway in SLE model mice. The proportion of Tfh cells was significantly correlated with the metabolism of LPE metabolites, and pla2g2f was a potential molecule that JP regulated LPE metabolism and affected Tfh cells. Cell experiments confirmed that JP downregulates pla2g2f expression and suppresses Tfh cell polarization in vitro. Molecular docking showed stable binding of JP active components (Cafestol, Daidzein, Isoliquiritigenin, Rifampicin, and Neochlorogenic acid) to PLA2G2F.

CONCLUSION:

JP can inhibit pla2g2f that involved in LPE metabolism to regulate the differentiation of Tfh cells and alleviate SLE disease. These findings provide a new perspective on the immune metabolic regulation of JP.

544

项与利福平相关的新闻（医药）

2025-12-05

·家属说慢病新药新疗法资讯

【II期临床试验】肝损伤新药临床！口服新药QR12000招募乙肝、丙肝等原发性肝脏疾病引起的慢性肝损伤或肝硬化的肝功能损害患者！

#肝病临床试验 #QR12000 #朗来科技 #血管紧张素II受体—脑啡肽酶双重抑制剂 #肝损伤新药临床招募 #肝功能损害新药临床招募简要入排本临床药物为血管紧张素II受体-脑啡肽酶双重抑制剂；目前招募肝损伤患者；需满足以下所有条件：既往原发性肝脏疾病（如乙型肝炎、丙型肝炎、酒精性肝病等）引起的慢性肝损伤或临床诊断为肝硬化，经Child-Pugh分级为A级、B级的肝功能损害者；服用试验药物前至少28天内未用药，或有稳定的治疗肝功能损害、并发症及其他伴随疾病的用药方案者，且用药不需要调整；排除药物性肝损伤、肝移植史、肝衰竭、肝性脑病、肝细胞癌（巴塞罗那分期为0期或获得根治性治疗效果者除外）、肝肾综合征、食管胃底静脉曲张破裂出血等研究者认为不合适的患者；排除胆道梗阻者。研究中心山东济南具体启动情况以后期咨询为准【研究中心若有更新请拉至文末查看】试验名称 QR12000复方片在肝功能损害和肝功能正常参与者中的药代动力学和安全性研究。试验药物 QR12000是由武汉朗来科技发展有限公司自主研发的新型血管紧张素受体-脑啡肽酶双重抑制剂（ARNI），为复方制剂（成分包括QR01019钾盐和QR12001铵盐，后者为沙库巴曲铵盐）。其研发基于全球已上市的沙库巴曲缬沙坦钠片（诺欣妥®）进行改良创新，旨在通过两种药物的协同作用实现更优的降压效果及心脏保护作用。此外，现有数据提示，QR12000的肝毒性风险较低。值得一提的是，诺欣妥®是全球首个血管紧张素受体脑啡肽酶抑制剂（ARNI）类药物，已在国内获批用于治疗射血分数降低的慢性心力衰竭和原发性高血压。研究药物：QR12000复方片（I期）登记号：CTR20253455 试验类型：平行分组适应症：肝损伤申办方：武汉朗来科技发展有限公司延伸阅读朗来科技是一家处于临床阶段的创新药研发公司，现有员工近300人，分别在武汉国家生物产业基地和上海浦东新区建立了国际化研发中心。公司遵循关注临床重大需求，兼顾品种特色的差异化立项研发策略，在自身免疫、呼吸系统、心血管等领域已开展多项药物研发。拥有在研管线20余条，均具有较高的差异化和领先性。此外，公司多个管线获得多个国际世界500强药企的青睐，具有良好的知识产权授权前景。备注：以上信息来源于网络注：上下滑动可查看全部内容用药周期 QR12000复方片的规格：50mg/100mg(QR01019/QR12001)；用法用量：1片50mg/100mg(QR01019/QR12001)；用药时程：单次给药。入选标准 1、自愿参加临床试验并签署书面知情同意书，能够理解本试验的程序和方法，能按试验要求完成全部试验过程。 2、签署知情同意书当日年龄18至70周岁（包括两端值），男女均可。 3、体重：男性≥ 50kg，女性≥ 45kg；体重指数（BMI）在18.0~32.0kg/m2范围内（含18.0和32.0）。 4、参与者（包括伴侣）愿意自筛选至试验药物给药后3个月内无生育计划且自愿采取避孕措施，且无捐精捐卵计划。 5、绝对GFR（以CKD-EPI公式计算）≥60mL/min。 6、肝功能损害参与者还需满足以下所有条件：往原发性肝脏疾病（如乙型肝炎、丙型肝炎、酒精性肝病等）引起的慢性肝损伤或临床诊断为肝硬化，经Child-Pugh分级为A级、B级的肝功能损害者。 7、肝功能损害参与者还需满足以下所有条件：服用试验药物前至少28天内未用药，或有稳定的治疗肝功能损害、并发症及其他伴随疾病的用药方案者，且用药不需要调整（包括用药种类、剂量或服药频率）。排除标准 1、有血管性水肿病史者、遗传性或特发性血管水肿患者和/或双肾动脉狭窄病史者。 2、可疑对研究药物中任何成分有过敏史者，或过敏体质。 3、既往接受过经研究者判断会影响药物吸收、分布、代谢、排泄的手术者；或筛选前4周内接受过外科手术者；或计划在试验期间进行外科手术者。 4、给药前3个月内献血或大量失血（> 400mL）者，接受输血或使用血制品者，或计划在试验期间或试验结束后3个月内献血者。 5、药物滥用者或给药前1年内使用过软毒品（如：大麻）或硬毒品（如：可卡因、苯环己哌啶等）者，或尿药物滥用筛查试验阳性者。 6、给药前3个月内每日吸烟量多于5支者，或试验期间不能停止使用任何烟草类产品。 7、给药前3个月内酗酒者（每周饮用14个单位的酒精：1单位=啤酒250mL，或烈酒25mL，或葡萄酒83mL）；酗酒定义为大约2小时内5次或以上饮酒；或试验期间不愿意停止饮酒或任何含酒精的制品，酒精呼气试验阳性者。 8、不能耐受静脉穿剌，或有静脉采血困难者，或有晕血、晕针史者。 9、使用试验药物前14天内接种疫苗或减毒活疫苗，或计划会在试验期间接种疫苗者。 10、HIV抗体阳性者；若梅毒抗体阳性者需增加快速血浆反应素试验（RPR）检测，如RPR同时阳性，需排除。 11、筛选前3个月内使用其他临床试验药物或计划在本研究期间参加其他临床试验者。 12、对饮食有特殊要求，不能遵守统一饮食者。 13、妊娠或哺乳期女性，或女性参与者在筛选前3个月内使用长效雌激素或孕激素注射剂或埋植片、30天内使用口服避孕药或2周内发生非保护性性行为者。 14、参与者可能因为其他原因而不能完成本研究或经研究者判断具有其它不宜参加试验原因者。 15、肝功能正常参与者如符合以下任一排除标准，需排除： a) 肝损伤史； b) 筛选时患有循环系统、内分泌系统、神经系统、消化系统、呼吸系统、血液系统、免疫系统、精神疾病及代谢异常等任何临床严重疾病者或可能干扰试验结果的任何其他疾病； c) 筛选期体格检查、生命体征、实验室检查、12导联心电图、腹部彩超、胸正位片等检查异常经研究者判断有临床意义，或心电图示QTc间期（QTcF）男性>450msec，女性>470msec； d) 有体位性低血压或晕厥病史者，或有高血压病史者；或筛选期收缩压＜90mmHg和或舒张压＜60mmHg者；或收缩压≥140mmHg或舒张压≥90mmHg者； e) 乙肝表面抗原、丙肝抗体任一指标筛查呈阳性者； f) 使用研究药物前4周内使用过任何药物者（包括中草药、保健品等）。 16、肝功能损害参与者如符合以下任一排除标准，需排除： a) 参与者存在下列任何一种情况：药物性肝损伤、肝移植史、肝衰竭、肝性脑病、肝细胞癌（巴塞罗那分期为0期或获得根治性治疗效果者除外）、肝肾综合征、食管胃底静脉曲张破裂出血等研究者认为不合适的患者； b) 胆道梗阻者； c) 除肝脏原发疾病本身外，筛选时患有其他严重器官系统性严重疾病，包括但不限于胃肠道、呼吸系统、肾、神经、血液、内分泌、肿瘤、免疫、精神或心脑血管疾病，且经研究医生判定不适合参加本试验者； d) 筛选期体格检查、生命体征、实验室检查、AFP、12导联心电图、腹部彩超、胸正位片、常规脑电图等检查异常经研究者判断不适合继续参加试验者；或心电图示QTc间期（QTcF）男性>470msec，女性>480 msec； e) 有体位性低血压或晕厥病史者，或筛选期收缩压＜90mmHg和或舒张压＜60mmHg者；或既往有高血压病史且现在合并降压药物治疗者，或筛选期收缩压≥150mmHg或舒张压≥100mmHg者； f) 给药前4周内服用除稳定治疗肝功能损害、并发症药物外其他伴随药物者，且稳定用药可能与研究药物有相互作用的合并用药（见附录5），如CYP3A4肝药酶强诱导或强抑制剂（利福平、伊曲康唑等）、CYP2C9肝药酶强诱导或强抑制剂（卡马西平、氟康唑等）、OATP1B1或OATP1B3转运体的底物和强抑制剂（环孢素、克拉霉素等）、ACEI类药物、阿利吉伦、ARB类药物、他汀类药物、西地那非、锂剂等。更多项目信息请参考： http://www.chinadrugtrials.org.cn/index.html 温馨提示：文章入排信息来源于国家临床试验官网公示信息，具体情况以实际咨询为准！报名方式参与临床试验，获取国际前沿新药使用机会！更有一线专家团队为你的治疗保驾护航！【印塔健康】目前有乙肝、脂肪肝、银屑病、特应性皮炎、类风湿性关节炎、强直、高血压、高血脂、糖尿病、贫血、阿尔茨海默症、溃疡性结肠炎、红斑狼疮、哮喘、青光眼、黄斑变性、慢阻肺、间质性肺病、肺纤维化......等慢病临床试验正在招募患者！扫描下方二维码添加医学运营一对一咨询或点击左下角“阅读原文”直接报名！我们将会在24小时内（工作日）与您电话或微信联系，请保持手机畅通！ End 【重要提示】印塔健康旗下公众号【家属说慢病新药新疗法资讯】所有文章信息仅供参考，具体治疗谨遵医嘱！ RECOMMEND 推荐阅读 1 AZD0780招募动脉粥样硬化性心血管疾病 2 吸入用TQC3721混悬液招募COPD 3 单抗新药SCTT11招募甲状腺眼病

2025-12-04

·阅航生物

Nature Reviews Microbiology | 细菌代谢在抗菌药物耐药性中的作用

点击蓝字 | 关注我们本文转自：微生物与免疫细菌代谢与抗生素治疗之间存在复杂的双向关系。一方面，抗生素通过靶向细胞代谢发挥作用。另一方面，细菌代谢状态深刻影响抗生素生物学特性——涵盖药物疗效、抗菌素耐药性（antimicrobial resistance，AMR）演化及耐药机制。鉴于AMR对全球现有抗生素库及传染病治疗能力构成重大威胁，阐明此类关系对改善公共健康至关重要。然而，量化代谢对抗生素活性及耐药性演化的贡献仍具挑战。一篇发表于Nature Reviews Microbiology的综述系统探讨代谢与抗生素治疗间的多维相互作用，阐述抗生素靶向代谢的作用机制，继而聚焦代谢对抗生素生物学三大核心领域的独特影响——药物疗效、AMR进化路径及耐药分子机制，最后评述代谢在临床实践中的相关性，并展望基于代谢的个体化抗菌治疗策略。深入解析这些关联对全球科学界应对AMR危机、开发新型有效疗法具有关键意义。主要内容抗生素的发现堪称现代医学最具变革性的成就之一，其应用使人类平均寿命延长逾20年。抗生素不仅彻底革新了细菌感染的治疗方式，更为复杂医疗程序（如化疗与器官移植）及常规护理（如拔牙与分娩）提供了关键感染控制保障。作为抵御常见急性感染的首道防线，抗生素可高效治愈化脓性链球菌所致咽炎、金黄色葡萄球菌引发的皮肤感染以及淋病奈瑟菌导致的性传播疾病。抗生素的广泛使用也催生了抗菌药物耐药性（antimicrobial resistance，AMR）——细菌在临床抗生素浓度下仍能存活增殖的现象，导致治疗失效。临床与农业领域的抗生素滥用加剧了AMR流行，现已被全球公认为重大健康危机。随着多重耐药菌激增及有效抗生素减少，预测表明2025至2050年间全球将有超1.69亿人死于AMR相关感染。细菌AMR主要由遗传机制驱动。通过自然遗传变异克隆扩增或移动遗传元件水平转移获得。无论获取方式如何，AMR机制通常可分为三大类：改变药物转运动力学，降低细胞内药物浓度；直接抗生素灭活，通常由酶水解介导；以及抗生素靶位点的修饰，如青霉素结合蛋白中阻止药物结合的突变。总的来说，这些机制严重威胁现有抗生素库的有效性，尤其在新药研发滞后于细菌进化速度的背景下。细菌对抗生素的应答机制仍是核心研究领域。最新研究表明细菌代谢——涵盖所有分解与合成代谢过程（基因、通路、代谢物及互作网络）——不仅受AMR影响，更深度调控耐药性形成。作为细胞功能的核心引擎，代谢为基因表达、蛋白合成、防御机制等关键活动提供能量与资源。这种复杂性使代谢成为抗生素治疗与应答各环节的调控枢纽。细菌代谢与抗生素治疗存在双向互作。代谢状态影响药物疗效，抗生素亦改变代谢通路。该互作揭示靶向代谢对抗AMR的巨大潜力。外源代谢物导入或特定通路上调可恢复耐药菌对抗生素的敏感性。这些发现为应对AMR提供了新视角，凸显代谢此前被低估的调控价值。鉴于细菌代谢与抗生素应答研究的迅猛发展，本综述旨在系统阐述代谢对抗生素的多维影响机制（图1）。首先总结抗生素对代谢的重编程作用，继而探讨代谢对药物疗效、AMR进化动力学及耐药机制的反向调控，最后评述代谢在哺乳动物宿主中的临床相关性及基于代谢疗法的抗AMR潜力。本文强调深入解析代谢-抗生素互作的必要性，并为下一代个体化抗菌疗法提供理论框架。图1. 抗生素与代谢之间的相互作用抗生素对代谢的影响抗生素作为靶向细菌细胞过程的小分子化合物，通过干扰生长或存活发挥抗菌作用。依据作用模式可分为杀菌剂（诱导细胞死亡）和抑菌剂（抑制细胞生长）。近期研究揭示两类药物对代谢的不同扰动机制，为阐明其作用机制提供新视角（图2）。图2.杀菌剂和抑菌剂利用新陈代谢来发挥其功能通常，杀菌抗生素通过抑制基本的细胞靶点诱导细胞死亡，除了一些例外情况，这些靶点通常与DNA复制（例如氟喹诺酮类）、蛋白质合成（例如氨基糖苷类）和细胞壁合成（例如β-内酰胺类、头孢菌素类）有关。在每种情况下，产生的细胞内损伤通常与药物的作用模式一致。例如，氟喹诺酮类药物抑制DNA旋转酶和拓扑异构酶IV，导致有毒的双链DNA断裂；氨基糖苷类药物靶向30S核糖体亚基，导致蛋白翻译出错和毒性应激。除直接损伤外，其诱导代谢稳态失衡是细胞死亡的第二层机制。杀菌剂暴露会立即触发应激反应网络的上调，包括SOS和严重反应。同时因修复系统能量需求增加，导致电子传递链、TCA循环及碳氧化途径失调。与这些影响一致，在杀菌暴露后，在不同的细菌物种中观察到ATP水平、耗氧率和活性氧物种的增加。例如，暴露于氨苄青霉素的大肠杆菌的单细胞RNA测序显示出TCA循环、甘氨酸代谢和糖酵解基因表达失调的明显迹象，与群体水平的测量结果一致。同样，多项研究报告称，用一系列抗生素处理牛分枝杆菌会增加细胞内ATP水平。有趣的是，经抗生素处理后1.5小时内ATP水平可激增4-5倍。最终，这种代谢失调会导致细胞毒性，再加上最初的靶点抑制，最终导致细胞死亡。我们注意到，所描述的每个方面对细胞死亡的贡献程度在历史上一直存在争议，并且可能因条件而异。根据代谢限制，细胞损伤通过不同的途径发生。对于革兰氏阳性和革兰氏阴性细菌的喹诺酮类、氨基糖苷类和β-内酰胺类治疗，有氧条件下的治疗通常与TCA循环和NADH耗竭引起的氧化损伤有关。相比之下，在厌氧条件下，相同的抗生素会促进糖酵解的增加——积累中心碳代谢物（例如葡萄糖和丙酮酸）——并产生不同的反应性代谢副产物（例如反应性亲电物种）。此外，尽管完全不同的杀菌类别最终会失调中枢代谢，但中间途径差异很大，这受到抗生素特异性作用机制的影响。例如，β-内酰胺处理诱导细胞壁合成和降解的无效循环，从而通过特定的细胞壁合成机制消耗细胞资源并增强杀伤性。此外，对于环丙沙星和氨苄西林的毒性，嘌呤生物合成需求的增加被发现是关键。庆大霉素的情况并非如此，这表明核苷酸限制可能对某些药物具有特异性，但对其他药物则没有。仍然需要更深入地了解药物特异性代谢途径及其与主要药物靶点的相互作用。杀菌剂通过上调能量代谢相关中枢通路（如电子传递链、三羧酸循环）发挥作用，而抑菌剂则通过限制能量利用、大分子生物合成及蛋白质翻译降低代谢活性。这种生长抑制可诱导独特代谢状态。氯霉素与利奈唑胺治疗导致能量代谢物异常积累；蛋白质组学分析证实金霉素显著下调糖酵解、糖异生、丙酮酸代谢及三羧酸循环活性。值得注意的是，抑菌剂在高浓度时可呈现杀菌效应（反之亦然），此现象模糊了两类药物的功能界限。当前学界对代谢抑制是否直接引发细胞死亡，或特定条件触发“类杀菌”激活过程尚未达成共识，需深入研究以阐明其动态机制。抗生素治疗的潜在后果是形成耐受性持留菌，这在慢性感染中很常见（框1）。传统认为持留菌随机产生或由环境压力诱导，使细菌亚群进入代谢惰性状态。其形成机制与SOS反应、严谨反应、（p）ppGpp信号传导及ATP耗竭密切相关，毒素-抗毒素系统、转运RNA甲基化修饰和蛋白质降解异常亦参与调控。抗生素治疗可通过抑制转录、翻译等关键过程增加持留菌形成频率，亚致死浓度还能激活应激反应、次级信使通路及毒力因子促进持留态转化。关于持留菌形成机制的详细讨论已在其他地方进行了综述。总体而言，抗生素显著重塑细胞代谢状态，而这些代谢变化可反馈增强药物作用，进而差异化影响细菌生长、抗生素选择压力及长期进化适应。因此，除解析抗生素治疗后代谢改变外，亟需在药物暴露前/期间表征细胞代谢状态，以深入理解微生物存活机制及后续抗菌药物耐药性演化路径。代谢对抗生素的影响鉴于抗生素治疗对细菌代谢的显著影响，治疗前细胞的代谢状态亦可调控抗生素反应，甚至通过代谢途径调节药物的预期作用机制及下游代谢失调。这种互作关系在结核分枝杆菌中尤为显著——其独特的代谢特征与多样化抗生素治疗方案共同塑造了复杂的耐药表型（图3）。近年来，相关机制研究已拓展至其他病原体与环境。本文通过解析代谢对抗生素疗效、耐药性演化及耐药机制的三重影响，系统阐述代谢在细菌抗生素应答中的核心作用。图3. 代谢调控结核分枝杆菌抗生素耐药性、耐受性与致死率的独特机制抗生素疗效确定代谢在抗生素致死率中的作用历来具有挑战性。由于代谢与生长密切相关，改变代谢活动的条件也会影响生长速率。此外，生长和抗生素疗效之间的关系更容易量化，因此以前一直是一个主要焦点。最常见的是，据报道，细菌生长率与杀菌抗生素的效率成正比。也就是说，杀菌抗生素通常被证明对快速增长的细菌种群最有效。然而，生长速率和代谢活动并不是普遍相关的，之前的研究经常将生长效应与代谢效应混为一谈。最近的研究发现，这种关系更加复杂。例如，细胞生长速率和细胞死亡之间的线性关系取决于环境条件，突出了这种关系的生理约束；通过改变抗生素类型、碳源和盐浓度来改变环境可以改变斜率或截距的大小。此外，充分的代谢刺激已被证明可以促进抗生素杀死不生长的持久细胞，从而表明代谢的独特作用。这些发现表明，虽然在某些条件下生长可能是抗生素疗效的指标，但代谢对抗生素疗效的独特影响值得独立研究。增强抗生素活性多项证据表明细胞代谢状态独立于生长速率直接调控杀菌抗生素疗效。在多种条件下，抗生素活性与代谢状态的相关性显著高于生长速率。同样，成功根除大肠杆菌和金黄色葡萄球菌已被证明需要代谢组重塑。这种代谢效应也解释了既定的抗生素剂量-反应关系。例如，接种物效应——一种众所周知的现象，描述了随着细胞密度的增加杀菌效果的降低——也基于代谢，更具体地说，是ATP浓度和密度抑制之间的权衡。鉴于已观察到不同抗生素类别和临床环境中的接种物效应，本研究凸显代谢在驱动体内抗生素应答中的核心作用。与这些发现一致，特定代谢物刺激可药物特异性提升抗生素致死率。在某些情况下，这些效应可能部分可以通过质子动力（PMF）的代谢刺激来解释。特别是对于带正电荷的氨基糖苷类，PMF增加了细胞内药物摄取，从而提高了抗生素的致死率。例如，添加糖酵解代谢物（如葡萄糖、甘露醇和果糖）可以提高庆大霉素对耐抗生素大肠杆菌和金黄色葡萄球菌的疗效。值得注意的是，这些观察结果在体内是可重复的，庆大霉素与甘露醇联合使用使导管生物膜的存活率降低了近1.5个数量级，并阻断肾脏感染扩散。虽然这些结果说明了代谢刺激在病原体治疗中的益处，但它们也强调了单独研究代谢的必要性。例如，细胞呼吸与PMF驱动的药物转运在氨基糖苷类致死率中的相对贡献仍未完全被理解。除了增强药物摄取外，刺激代谢活动还可以通过次级代谢效应增强抗生素疗效。例如，将TCA循环中间体富马酸盐与抗生素妥布霉素结合，可杀死与囊性纤维化相关的机会致病菌铜绿假单胞菌。从机制上讲，富马酸盐通过TCA循环激活细胞呼吸并刺激质子动力。值得注意的是，即使在存在药物进口的情况下，抑制TCA循环也能恢复抗生素耐受性，这表明TCA循环活性对于代谢物补充和妥布霉素发挥作用至关重要。这些发现强调了下游代谢过程（独立于药物摄取）在驱动抗生素致死率方面的关键作用。同样，激活结核分枝杆菌的呼吸已被证明可以预防耐药性和耐药性的出现。添加小巯基使结核分枝杆菌保持活跃的代谢状态，产生“氧化爆发”，增加氧气消耗和活性氧的产生，促进细胞死亡。降低抗生素疗效虽然高代谢活性可以加强抗生素治疗，但低代谢活性可以防止抗生素暴露。在许多病原体和环境中都观察到了这些保护作用，并且可以通过多种机制发生。例如，富马酸通过激活TCA循环提高了铜绿假单胞菌的氨基糖苷类疗效，而代谢产物乙醛酸则诱导了抗生素耐受。保护作用归因于乙酰辅酶A通过乙醛酸分流器的转移抑制了细胞呼吸。同样，结核分枝杆菌的抗生素耐受是通过抑制TCA循环代谢来介导的。此外，蛋白质组学分析证实溶藻弧菌的中心碳代谢抑制可增强左氧氟沙星耐受性。低代谢状态可能是对环境刺激的反应，如营养剥夺，这会降低抗生素的疗效。例如，限制特定氨基酸通过下调能量产生、戊糖磷酸和核苷酸代谢来保护鲑鱼免受氨苄青霉素的侵害，而不影响生长速度或抗性基因表达。这些影响在生物膜中进一步加剧，细菌存在于各种异质的代谢休眠状态中（图4）。在生物膜内，细菌的抗生素耐受性比治疗所需的浓度高出数百到数千倍。虽然生物膜结构本身可以防止抗生素渗透，但营养限制导致的有氧代谢减少主要有助于抗生素耐受性。营养恢复可以逆转这种效应，使生物膜细胞对抗生素敏感。图4. 生物膜的独特性质通过改变新陈代谢赋予抗生素耐药性群体行为相关表型亦与独特代谢状态关联。例如，铜绿假单胞菌等群集细菌表现出暂时的耐受性，而cbrA等代谢基因与毒力和抗性表型有关。细菌群体运动会带来高代谢负担，导致与抗生素疗效相关的通路整体下调，包括糖酵解和丙酮酸异化、TCA循环和氨基酸生物合成。这些发现强调，在一些复杂的环境中，代谢和AMR之间的复杂相互作用尚未完全阐明。耐受性也与密度依赖信号有关，如群体感应（quorum sensing，QS）。QS允许细菌采取合作状态，并影响生物膜形成、毒力因子合成和群集。QS还通过下调葡萄糖摄取、戊糖磷酸通路和从头核苷酸生物合成来调节中枢代谢。这引发了类似的问题，即代谢对耐药性和分组细菌状态的影响范围。这些复杂互作机制亟待深入解析，尤其需阐明代谢在多通路调控耐药性中的核心作用。新型抗菌药物耐药性的演变抗生素暴露后，代谢通过直接与间接途径驱动AMR演化。杀菌抗生素通过刺激氧化应激、激活SOS反应及DNA修复机制显著提高突变率，增加耐药突变产生概率。例如氨苄西林、环丙沙星或卡那霉素（而非抗菌肽）处理使突变率提升3-4倍，SOS介导的突变对铜绿假单胞菌和结核分枝杆菌临床株及生物膜中的AMR发展至关重要。除了新发突变，AMR还通过水平基因转移（horizontal gene transfer，HGT）演化，其中接合性质粒转移（细胞直接接触传递）通过接合、转化和转导发生，是耐药性传播的核心机制。质粒编码自我复制及多重AMR基因，即使无抗生素选择压力仍可维持耐药性。生物膜环境显著促进接合作用，加速抗性基因扩散。结合效率（动力学转移速率）受细胞代谢状态的影响，因为结合是能量密集型的（图5）。高碳浓度和活跃的生理状态可以大幅提升质粒转移动力学速率。转移后，与质粒再循环和宿主建立相关的能量需求带来了短暂的代谢成本，称为质粒获取成本，这在代谢效率高的细胞中更高，可能是由于能量限制。重要的是，这些成本与没有质粒的生长速度无关。因此，与生长分开，代谢会影响抗生素耐药性侵入新环境的程度。质粒对宿主施加了长期的能量需求（维护、拷贝数等）。这种适应成本主要来自与蛋白质产量增加相关的代谢负担，并限制了质粒传播的范围和轨迹。这些短暂的（获取）和长期的（适应）成本都会导致微生物群落的潜在竞争优势或劣势，从而导致进化结果。图5. 代谢通过接合作用促进抗微生物耐药性的进化除了结合，代谢也可能影响其他HGT模式。例如，调节新陈代谢的QS也调节细菌的能力。通过这种方式，代谢可能与为细菌提供修复受损基因或获得新的有利特征的机制有关。同样，转导取决于细菌的生长；这引发了关于不同细菌代谢状态如何影响转导噬菌体感染细菌的能力的问题。此外，代谢状态也可以作为药物耐受和遗传耐药性之间的表型桥梁。休眠通常与抗生素耐受状态有关，已被证明会促进随后的真正耐药性，并先于耐药性演变。此外，延长生存期也可能有利于随后的基因转移事件，尽管其直接联系仍有待观察。耐药性随机性使代谢失调与AMR的因果关联研究面临挑战。尽管如此，越来越多的证据突显了代谢在塑造AMR进化中的作用。例如，可转移质粒上代谢基因的存在被证明可以防止抗生素治疗，拓宽了直接抗生素选择下的质粒和代谢基因可能赋予AMR的背景。这是通过调节质粒相关的代谢作用还是直接通过基因功能本身发生的，还有待观察。此外，碳和能量代谢被发现可以在两种不同的营养条件下限制AMR对三种作用机制不同的抗生素的进化。对190个进化种群中代谢物的综合分析表明，碳和能量代谢在获取速度和模式方面都强烈限制了抗生素耐药性的进化。未来需深入解析特定代谢通路在AMR大背景下的调控网络。一级和二级抗菌药物耐药机制众所周知，抗生素通过选择耐药菌株在致死浓度下存活，经典机制包括靶点修饰、药物灭活及转运改变。近年研究表明代谢在AMR中发挥双重作用：既可直接作为耐药决定因素被抗生素选择，亦可通过代谢效应补充或放大经典耐药机制（图6）。图6. 抗菌药物耐药性的经典和代谢调控机制核心代谢基因突变或表达水平改变可导致体外AMR。在某些情况下，耐药性发生的机制是明确的，因为受影响的代谢基因与特定的药物类型直接相关。例如，由于甲氧苄啶和磺胺甲恶唑（trimethoprim and sulfamethoxazole，TMP-SMX）共同抑制叶酸的合成，叶酸是核苷酸生产的关键前体，对这种常见药物组合的耐药性直接影响菌株的代谢。这种阻力可能以多种方式出现。例如，在金黄色葡萄球菌、肺炎链球菌和流感嗜血杆菌中，编码二氢叶酸还原酶的dhfr基因突变可导致甲氧苄啶耐药性。令人担忧的是，最常见的dhfr变体允许药物浓度比抑制易感分离株所需的浓度高1000倍。TMP-SMX耐药性也可能通过过量产生二氢叶酸还原酶（dihydrofolate reductase，DHFR）或二氢蝶酸合酶（dihydropteroic acid synthase，DHPS）的酶促药物靶点而发生。此类“代谢旁路”经DNA启动子突变激活，有效抵消药物对叶酸合成的抑制。尽管细菌代谢的主要作用直接干扰药物与靶点的相互作用，但其次要作用也可以防止抗生素治疗，尽管是间接的。由于不同抗生素的作用往往集中在共同的下游代谢通路上，部分代谢机制可提供广谱保护。例如，与中心碳和能量代谢相关的基因与大肠杆菌对三种杀菌抗生素的耐药性有关。事实上，这些基因的过表达增加了耐药性，突变本身在致病基因组中非常普遍，突显了它们的临床相关性。其他与药物无关的方法也得出了类似的结论。例如，沙门氏菌基因组的高度准确的耐药性预测确定了几个以前未被重视的代谢基因在耐药性中的潜在作用，包括那些参与氧化应激和电子转运的基因。同样，葡萄糖利用特异的代谢抗性赋予对羧苄青霉素与环丙沙星的交叉耐药。除了代谢特异性变化外，经典AMR机制亦可改变细胞代谢状态，此类代谢变化被视为耐药的次要后果，但其在AMR表型中的直接贡献尚未明确。例如调控元件CbrAB/envZ-ompR突变通过下调孔蛋白表达减少抗生素摄取，导致多粘菌素B、环丙沙星等药物疗效降低。孔蛋白表达改变同时影响氨基酸、糖及离子运输，但药物摄取对营养动力学的具体作用仍有待验证。某些耐药机制存在意外代谢权衡：利福平耐药基因rpoB突变在赋予耐药性的同时促进β-葡萄糖苷利用。综上，代谢在AMR中的完整作用仍与经典机制混为一谈。尽管已经确定了AMR的一些有趣的代谢机制，但这些关系充满了未解之谜；众所周知，代谢网络是复杂的、冗余的和补偿性的。因此，简化模型（如“低呼吸/代谢活性赋予保护”）难以全面解释耐药产生。该概括未涵盖所有细菌反应，例如大肠杆菌、铜绿假单胞菌等群体中生长较快菌株反而受大环内酯类保护（无基因突变参与）。这些矛盾凸显基础认知与方法学局限——传统技术（如波动分析）无法同步捕捉抗生素诱导突变、耐药进化及群体行为等多维动态。突破此瓶颈需发展新一代研究方法以揭示代谢-AMR的深层互作网络。这些缺点表明，在未来几十年里，仍有许多方法论工作要做。哺乳动物宿主的临床后果考虑到宿主环境，抗生素疗效和细菌对抗生素治疗的反应似乎越来越复杂。作者希望读者阅读其他更详细地描述体内病理的文章，但请注意，由于不同的代谢宿主组织环境，细菌代谢可能会发生显著变化。例如，脓肿通常是缺氧和营养有限的；这可能会迫使细菌采取厌氧呼吸或发酵途径，降低对需氧摄取的氨基糖苷类药物敏感性。同样，在由大肠杆菌等病原体引起的尿路感染中，不同pH值的尿液中尿素和其他氮源的可用性可以促进代谢适应。这些变化对靶向叶酸合成途径的TMP-SMX等抗生素的疗效具有潜在影响。相比之下，囊性纤维化患者肺部富含黏蛋白的环境为铜绿假单胞菌提供独特碳源，诱发代谢转换并促进抗生素耐受。这些部位特异性代谢适应强调需结合病原体与宿主代谢状态设计治疗方案，因感染灶的代谢与空间异质性可显著改变药物效应。与这些发现一致，3500余株临床大肠埃希菌病原体的代谢基因突变谱揭示广阔的进化空间。全基因组CRISPR干扰筛选、转录组学与代谢组学联合分析表明，呼吸链、核糖体生物合成及核苷酸/氨基酸代谢通路构成异烟肼耐药结核分枝杆菌205菌株的药物脆弱性靶点。解析特定环境相关突变及其获益机制仍是活跃研究领域。除了当地宿主环境的代谢特征外，与驻留微生物群的相互作用还增加了另一层复杂性，因为这些微生物群落积极影响细菌行为、抗生素浓度和生物化学特性。例如，肠道微生物群起着至关重要的作用，如碳水化合物发酵、维生素合成、免疫调节和生物活性代谢物的产生。这些微生物活动直接影响药物代谢，改变抗生素的有效性和毒性。已知几种抗生素会被肠道微生物群共同代谢，包括甲硝唑和氯霉素。重要的是，个体之间肠道微生物群组成的变异性导致了对相同抗生素治疗的不同反应，突显了个性化医疗的主要挑战。例如，肠道中胆汁酸浓度的变化会改变环丙沙星和美罗培南对大肠杆菌的疗效，并促进铜绿假单胞菌生物膜的形成。因此，阐明体内代谢因素对抗生素治疗、应答及后续进化的影响，是开发适配个体代谢-微生物特征疗法的关键。未来展望代谢深度参与细菌对抗生素应答的全过程，在开发新型抗生素及治疗策略时必须纳入考量。尽管代谢与抗生素治疗存在内在双向互作，当前研究主要聚焦抗生素对代谢的影响，而代谢如何调控药效、耐药演化及分子机制仍需系统阐释。深入解析复杂环境中的代谢网络将助力发现抗AMR新策略。生物膜中营养限制通过SOS/严谨反应增强耐受性，而营养补充可逆转此效应（小鼠模型已验证）；高密度环境下，葡萄糖刺激呼吸活动可克服大肠埃希菌、金黄色葡萄球菌及耻垢分枝杆菌对环丙沙星的密度依赖性耐受。在更大的相互作用网络和环境背景下更深入地了解这些关系，将有助于发现对抗AMR和/或最大限度地提高抗生素效用的新策略。就生物膜而言，对代谢作用的更深入理解提供了新的治疗前景。例如，研究表明，生物膜中的营养限制通过SOS或严格反应增加了对抗生素的耐受性。这些研究表明，通过营养补充促进代谢活动可能会限制耐受性和抗性，正如在小鼠模型中已经看到的那样。在历史上难以治疗的高密度环境下，葡萄糖刺激呼吸活动可克服大肠埃希菌、金黄色葡萄球菌及耻垢分枝杆菌对环丙沙星的密度依赖性耐受。采用新策略上调特定代谢通路是对抗抗生素耐药性和AMR的另一种有前景的方法。例如，利用氨基酸、TCA循环中间体和核苷酸等代谢产物可以恢复抗生素的致死性。其他药物也可能被设计为模拟抗生素活性并上调细菌代谢。例如，正在探索各种纳米粒子结构产生活性氧物种和氧化应激的能力。除了用佐剂补充抗生素外，独立利用代谢也可以作为一种抗菌策略。例如，合成工程铁螯合剂已被用于降低铁的生物利用度，导致生长抑制。使用这种创新设计的化合物的初步结果对金黄色葡萄球菌和鲍曼不动杆菌等生物体产生了中等至有前景的抗菌活性。其他利用铁代谢的策略包括使用镓等竞争金属来限制铁的吸收。镓化合物已被证明对与囊性纤维化、肺炎、慢性阻塞性肺病和一般伤口愈合相关的多药耐药性和机会性病原体有效。有趣的是，这些发现已经在许多环境中观察到，包括体外模型、体内小鼠模型、临床分离株和人类临床试验。尽管人们仍然担心这些药物的毒性作用，但其中一些化合物和类似化合物正在临床开发中。代谢干预效果具有情境依赖性。AMR演化及逆转不仅取决于当前代谢状态，更受历史选择压力影响。耐药菌株仅在原始进化环境或相似条件下维持耐药表型，而改变营养源恢复原始代谢效率可使其复敏。这表明有效代谢疗法需高度菌株特异性。长远看，环境与系统发育特征将决定代谢策略的普适性。除了菌株特异性外，利用宿主代谢为个性化抗生素治疗提供了一个尚未开发的机会，有可能更精确地改善治疗结果。目前的体外抗生素敏感性测试往往无法完全符合体内临床有效性，这突显了治疗传染病的一刀切模式忽视了关键的宿主-病原体、药代动力学和药效学因素。由不同感染部位和人与人之间的差异引起的代谢特异性因素可能会进一步导致这些差异。然而，这些因素在临床实践中仍未得到充分探索。此外，特定的微生物组环境可以调节抗生素活性和病原体行为。事实上，研究强调，肠道微生物组可以作为一个库，用于识别针对独特代谢环境量身定制的新的病原体特异性疗法。例如，抗生素、细菌素和微霉素等微生物组衍生药物有望成为精确的抗菌药物。特别是细菌素，在临床前模型中取得了成功；他们治疗了246只小鼠的铜绿假单胞菌肺部感染和248只牛和哺乳期妇女的乳腺炎。弥合基础研究和个性化医疗之间的差距需要明确的研究，将宿主介导和微生物组介导的代谢效应与观察到的临床差异联系起来。代谢在细菌对抗生素的反应中的复杂作用仍然不完全清楚，部分原因是缺乏优化的工具，无法将代谢效应与生长特异性或药物特异性的代谢效应区分开来。因此，必须设计分离代谢效应的方法。例如，代谢在典型外排AMR机制中的作用应从代谢物特异性和药物特异性转运蛋白中提取出来。此外，未来的技术，包括模拟和信息方法，在揭示新陈代谢的生长无关效应方面将非常有用。这些方法通常比物理量化方法更可行，包括基于通量的分析和动态全基因组建模，以及粗粒度方法。至关重要的是，生态进化模型将评估新策略的潜在演化后果，依托全基因组测序、质谱与预测建模整合多维数据。对抗AMR本质上是复杂的，需要病原体-环境-临床背景的特异性方案。构建综合代谢框架可推动传染病个性化治疗。患者生化特征、感染部位微环境及局部因素共同塑造体内代谢限制。深化代谢-AMR互作研究对开发下一代疗法、对提升全球AMR应对能力具有核心价值。关于细菌耐药机制研究，现在细菌单细胞转录组测序技术是一种有效的技术手段，该技术能够解析单个细菌细胞的基因表达异质性，例如，在环境压力（如抗生素暴露）下，细菌种群中可能存在功能迥异的亚群：部分细胞激活耐药基因通路，而其他细胞则进入休眠状态。单细胞转录组分析可精准捕捉这些细微差异，帮助阐明细胞命运决定的分子机制。武汉阅航生物科技有限公司主要提供单细胞转录组测序分析服务，已顺利完成多种真核单细胞转录组、细菌单细胞转录组测序分析。欢迎有需求的老师电话13163335846（微信同号）咨询相关技术服务。关于阅航生物阅航生物专注于时空组学测序和生物信息分析，以细菌、菌群单细胞转录组测序技术服务为特色。目前已成功完成上千例动物、植物、微生物样本单细胞转录组测序，为上百家科研院校提供生物信息分析服务。点击关注，获取更多资讯！

微生物疗法临床研究

2025-12-04

·北京医学感染与传染研究

抗菌化疗杂志 80卷 7-12期、增刊2、4期

Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review 抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述 Konstantinos Alexakis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771, 2 To be or not to be: the non-antimicrobial properties of common antimicrobials 生存还是毁灭：常见抗菌药物的非抗菌特性 Shivakumar Narayanan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783, SYSTEMATIC REVIEWS（系统综述） 3 Antibiotic-induced Bartter-like syndrome: a systematic review 抗生素诱发的巴特综合征样表现：系统综述 Megha Priyadarshi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791, 4 Liposomal amphotericin B prophylaxis in paediatrics: a systematic review 两性霉素B脂质体预防性用药在儿科中的应用：系统综述 Emma V Thorley and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802, ORIGINAL RESEARCH（论著） 5 Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study 婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究 Sarah F Hak and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812, 6 Plasmodium falciparum isolates: ex vivo drug response 恶性疟原虫分离株：体外药物反应 Edem Adika and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822, 7 Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia 低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827, 8 Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England 探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法 Ming Xuan Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836, 9 Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study 新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究 Yulia Butscheid and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848, 10 Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析 Alessandro Cozzi-Lepri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859, 11 Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model 基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型 Diego Vera-Yunca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868, 12 Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine 线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关 J R Macdonald and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877, 13 Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium 米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性 Kay Htaik and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884, 14 Early use of the novel antifungal rezafungin: a case series and literature review 新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述 H C Davidson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892, 15 Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach 基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量 Gisela Myrian de Lima Leite Dalla Rosa and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901, 16 Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade 过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关 Aliya El Nagar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906, 17 An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections 一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响 Mariagrazia Ciardo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914, 18 Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients 利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估 Xiaoping Shi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925, 19 Rapid susceptibility testing on urine for antimicrobial stewardship in general practice 全科实践中的尿液快速药敏试验助力抗菌药物管理 Patrick D J Sturm and Tanja Schülin Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932, 20 Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains 利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941, 21 In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains 新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性 Marie L G Attwood and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946, 22 Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions 中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性 Nadiia Mosiichuk and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950, 23 Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China 中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征 Zeqiang Zhan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963, 24 High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study 根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集 Zhengyu Luo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971, 25 Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus 抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响 Aliona S Rosca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979, 26 Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study 肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究 Lijuan Feng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987, 27 Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875 多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征 Jonathan Koong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992, 28 Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum 改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较 Doris Hillemann and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996, 29 Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations 由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转 Paschalis Paranos and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006, 30 Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France 瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构 Sofie M Edslev and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015, 31 Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections 抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估 Nischal Ranganath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024, 32 Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control 肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法 Ana Beatriz Gonçalves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031, 33 Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori 抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性 Paweł Krzyżek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043, 34 A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro 生殖支原体体外诱导产生的新型阿奇霉素耐药突变 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050, RESEARCH LETTERS（研究信函） 35 Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations 婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度 Jeffrey Harrington and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053, 36 Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis 两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法 Natacha Mrozek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056, 37 Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis? 头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？ Alexandra Morin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058, LETTER TO THE EDITOR（致编辑的信） 38 Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint 单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点 Miguel Villamarín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060, Journal of Antimicrobial Chemotherapy Volume 80, Issue 8 抗菌化疗杂志 80卷 8期 https://academic.oup.com/jac/issue Review(综述) 1 World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’ 世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇” Vazhayil Hari Krishnaprasad and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069 Original Research(论著) 2 Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023) 氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结 Helio S Sader and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079 3 High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid 利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究 Hitoshi Kawasuji and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091 4 Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium 缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析 Yukitaka Hayashi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099 5 Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial 为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验 Nusrat Shafiq and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108 6 An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy 用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型 Cole McGrath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116 7 Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa 黏液型铜绿假单胞菌纸片扩散法的优化与改进 Aixin Wang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125 8 HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022 乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查 Christine Watera and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134 9 Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women 与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究 Sharana Mahomed and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144 10 Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study 接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究 Javier García-Abellán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157 11 Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model 慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究 Midas B Mulder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168 12 Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据 Roberta Gagliardini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178 13 Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial 病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验 Hsin-Yun Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186 14 Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia 青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究 Pernilla Kihlberg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193 15 Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202 16 Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway 齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌 Yun-Dan Zheng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213 17 Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study 阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究 Tom C Zwart and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225 18 48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析 Elisa de Lazzari and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233 19 The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time 多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响 Trenton Honda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240 20 Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales 一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估 Christian Moguet and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246 21 Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究 Matteo Rinaldi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256 22 Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus 靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染 Robin H G A van den Biggelaar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268 23 Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm 基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279 24 Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy 意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件 Andrea Brenciani and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284 25 Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022 2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征 Corentin Poignon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294 26 Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections 具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁 Ye Jin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304 27 Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB 贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性 Simon E Koele and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313 28 Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study 头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究 Dimitrios Basoulis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322 Research Letters(研究信件) 29 Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring 达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告 Carlo Pallotto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324 30 A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs 韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174） Hyeonwoo Cho and Kun Taek Park Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326 31 Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report 时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告 Layla Pagnucco and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330 32 Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48 土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征 Astrid Rasmussen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331 Letters to the Editor(致编辑的信) 33 Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital 述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究 Jianjun Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332 34 Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response 产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复 Gulhadiye Avcu Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333 Corrections(更正) 35 Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD) 更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334 36 Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs 更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335 37 Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics 更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336 Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2 抗菌化疗杂志 80卷增刊2期 https://academic.oup.com/jac/issue SUPPLEMENT (补充) CANWARD 2007-23 加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告 Foreword(前言) 1 The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection 加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集 James C Hurley and Jean-Yves Madec Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1 Supplement Papers(补充论文) 2 Seventeen years of the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究17年（2007-2023年） George G Zhanel and Heather J Adam Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4 3 Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14 4 Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26 5 Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023） Anissa Brahami and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34 6 Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23） Heather J Adam and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44 7 Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23 加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023 Philippe Lagacé-Wiens and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53 8 Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23） Laura F Mataseje and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61 9 Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23) 加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23） Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71 10 Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23) 加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果 Andrew Walkty and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82 Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Classifying patients with invasive fungal disease: towards a unified case definition? 侵袭性真菌病患者分类：能否达成统一的病例定义？ Mehmet Ergün and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343, SYSTEMATIC REVIEW（系统综述） 2 Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis 早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析 ZhaoYi Tan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360, ORIGINAL RESEARCH（论著） 3 Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium 屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定 Maria Laura Ferrando and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368, 4 Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响 Rebecka Papaioannu Borjesson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374, 5 Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks 随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响 Parul Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383, 6 Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea 基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据 So Yun Lim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390, 7 A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme 摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准 Aymeric Jacquemin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398, 8 Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya 2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征 Diana Imoli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407, 9 Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection 经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响 Tao-Hung Ou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416, 10 Safety of topical tobramycin powder during operative treatment of fractures 骨折手术中使用局部妥布霉素粉末的安全性 Gregory M Schrank and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420, 11 Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS 复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析 Rinko Lau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427, 12 Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England 从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌 Satheesh Nair and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432, 13 Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics 克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用 Siddharth Singh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441, 14 Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446, 15 Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用 Xuemin Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458, 16 A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology 采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究 Joseph Meletiadis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465, 17 Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study 万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析 M Del Monte and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473, 18 Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient 异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现 Martyna Pociupany and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483, 19 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486, 20 Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database 使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析 Yongseop Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495, 21 Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024 2024年中国河南省HIV-1感染者传播耐药情况 Jinjin Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502, 22 Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性 Makiko Noda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512, 23 In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization 头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征 Clara Moretó-Castellsaguéand others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523, 24 Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates 达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用 David Luque Paz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529, 25 Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation 伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响 Wenjie Cui and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540, 26 Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up 加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响 Freshwork Ayalew Abegaz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549, RESEARCH LETTERS（研究快信） 27 TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient 治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染 Giovanni Mulé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552, 28 Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage 城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759 Xinyuan Qiu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555, 29 Characterization of multiresistance gene optrA in Bacillus subtillis from China 中国枯草芽孢杆菌中多重耐药基因optrA的特征分析 Yongliang Che and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557, 30 Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China 从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征 Fuqiang Ye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560, LETTERS TO THE EDITOR（致编辑的信） 31 Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events 关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论 Mi Zhou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562, 32 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study 关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论 Satoru Mitsuboshi Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563, 33 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response 住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564, Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead 长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战 Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586, 2 Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估 James C Hurley Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596, SYSTEMATIC REVIEWS（系统综述） 3 Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology 研究肺结核治疗的肺内药代动力学：方法学的系统综述 Isabella van der Feltz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608, 4 Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis 全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析 Christopher Larkin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621, ORIGINAL RESEARCH（研究论著） 5 Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium? 氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？ Paula Bierge and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629, 6 Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023 2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测 Nguyen Van Thanh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634, 7 Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia 哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性 Savan Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643, 8 Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia 连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度 Claire Roger and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653, 9 Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial 头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验 Tamara Klementová and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658, 10 Trends in antifungal use among hospitalized patients in the USA, 2018–23 2018-2023年美国住院患者抗真菌药物使用趋势 Dallas J Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664, 11 Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究 Louis Oudiane and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675, 12 In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium 甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性 Sofie Skovmand and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681, 13 A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model 基于群体药代动力学模型的左氧氟沙星剂量方案先验优化 Emmanuel Enard and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692, 14 Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis 危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析 Tingting Wu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704, 15 Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria 开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标 Irene Zaghi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713, 16 In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model 头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718, 17 Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial 健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验 Jinhee Jo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726, 18 Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application 抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示 Nathan Engel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731, 19 A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study 意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741, 20 Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study 使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究 Hiroki Katsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751, 21 Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial BALANCE临床试验中血流感染患者的临床病程 Sean W X Ong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758, 22 Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study 神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究 Qian Zeng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772, 23 Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates 肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景 Jayanth Balakuntla and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781, 24 Population pharmacokinetics of bictegravir in real-world people with HIV 现实中HIV感染者比克替拉韦的群体药代动力学 Pierre Ekobena and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789, 25 Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index 活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响 Teres Samuelsson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798, 26 Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa 在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806, 27 Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model 在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移 Solene Labaye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813, 28 Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms 针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用 Justin Halim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824, 29 Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France 2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验 L Sagaon-Teyssier and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833, 30 Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin 对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征 Emilia Cercenado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843, 31 Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA 美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构 Chih-Hao Hsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853, 32 Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii 鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征 Jingchen Hao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861, 33 Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones 各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征 Jing Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872, RESEARCH LETTERS（研究快报） 34 Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option? 奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？ Giulia Turicchi and Marco Bongiovanni Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874, 35 The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876, 36 Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas 携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播 Roberto Sierra and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879, 37 Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae 替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性 Julie Brousseau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881, LETTERS TO THE EDITOR（致编辑的信） 38 Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus 述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性 Karl Oldberg and Magnus Rasmussen Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883, 39 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究 Giancarlo Ceccarelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885, 40 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response 住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886, Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷增刊4期 https://academic.oup.com/jac/issue/80/Supplement_4 SUPPLEMENT（补充） Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 FOREWORD（前言） 1 Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 James C Hurley and Alan P Johnson Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1, SUPPLEMENT PAPERS（补充论文） 2 Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions 英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向 Alasdair P MacGowan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6, 3 The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations 英国抗菌化疗学会耐药性监测项目：方法与局限性 Michael Allen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21, 4 Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35, 5 Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48, 6 Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019 英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59, 7 Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019 英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71, 8 Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019) 英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年） Carolyne Horner and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86, 9 Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future 英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来 Benjamin J Parcell and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95, Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期 https://academic.oup.com/jac/issue VIEWPOINTS（观点） 1 Modification of antimicrobial susceptibility testing methods 抗菌药物敏感性检测方法的修改 Ian Morrissey and Jean B Patel Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888, 2 Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA 观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验 Ashley M Wilde and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891, REVIEWS（综述） 3 Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules 噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式 Cleo Anastassopoulou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901, 4 Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications 融合质粒的分子驱动因素：机制见解与进化意义 Ziyi Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911, ORIGINAL RESEARCH（研究论著） 5 Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry 泰国养猪业中出现与牲畜相关的MRSA克隆复合体398 Pawarut Narongpun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917, 6 Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series 长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告 Tomaso Beringheli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922, 7 Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections 细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点 Yao Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933, 8 The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用 Jiahui Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944, 9 Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study 接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究 Thibaut Gelé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953, 10 Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare 胞内分枝杆菌中与氯法齐明耐药相关的新型突变 Xiuzhi Jiang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957, 11 Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria 基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性 Mariana Romero-Gonzalez and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969, 12 In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin 体外进化揭示生殖支原体对莫西沙星的耐药机制 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977, 13 The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening 毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性 Weifeng Xu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988, 14 Molecular insights into carbapenemase-producing Enterobacterales from Senegal 塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征 Ousmane Sow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000, 15 Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients 老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型 Xianglong Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010, 16 In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China 在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性 Rongqi Lu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020, 17 Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain 从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒 Yao Zhu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025, 18 Multidrug resistance and recurrence in urinary bacteraemia among cancer patients 癌症患者中尿路菌血症的多药耐药性和复发情况 Ignacio Grafia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033, 19 Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection 在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药 Ping Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042, 20 Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals 伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险 Jirachaya Toyting-Hiraishi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056, 21 Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales 液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估 Anna Witkowska and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064, 22 Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus 毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性 Stephanie Toepfer and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078, 23 Ivermectin dosing for children under 2 years 2岁以下儿童的伊维菌素剂量 Wenyu Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081, 24 Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据 Alessandra Vergori and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091, 25 Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic 城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素 Geoffroy Liegeon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100, 26 Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry 在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究 D Armenia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106, 27 Sequential antibiotic exposure restores antibiotic susceptibility 序贯抗生素暴露恢复抗生素敏感性 Farhan R Chowdhury and Brandon L Findlay Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117, 28 Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study 在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现 Ling-Ya Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122, 29 Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt 埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性 Mohamed Eladawy and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132, 30 How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy? 在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？ Marie Gilbert and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138, 31 In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species 奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价 Corinne Pinder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149, 32 Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis 在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用 Christopher A Darlow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159, 33 High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon 喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高 Armando B D Djiyou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164, RESEARCH LETTERS（研究快讯） 34 SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants 新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性 Bram Spruijtenburg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166, 35 Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure? 替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？ Andrea Poloni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168, 36 Does the use of topical azoles have an impact on antifungal resistance? 局部使用唑类药物对抗真菌耐药性有影响吗？ Jean-Yves Maillard Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186, 37 Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy 接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况 Samir Benkouiten and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188, CORRECTION（更正） 38 Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189, Journal of Antimicrobial Chemotherapy Volume 80, Issue 12抗菌化疗杂志 80卷 12期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying ‘breakpoints in brackets’ 利福平单药治疗金黄色葡萄球菌感染：关于不应用“括号内折点”的考量 Sara E Boyd and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3191–3193, REVIEWS（综述） 2 The Achilles’ heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing 特洛伊木马的致命弱点？头孢地尔药敏试验的系统评价 Deny Tsakri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3194–3207, 3 Antifungal treatment strategies and their impact on resistance development in clinical settings 抗真菌治疗策略及其对临床环境中耐药性发展的影响 Norman Van Rhijn and P Lewis White Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3208–3226, ORIGINAL RESEARCH（论著） 4 Decrease in colistin resistance among young bovine and pig productions in France: relationship with colistin usage and stewardship measures 法国年轻牛和猪生产中多粘菌素耐药性的下降：与多粘菌素使用及管理措施的关系 Claire Chauvin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3227–3235, 5 Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments 接受联合抗病毒治疗的活动性血液系统疾病患者感染SARS-CoV-2后恢复抗癌治疗的时间 E Matteini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3236–3241, 6 From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV 从三联疗法到单一疗法：在多重耐药HIV感染且治疗经验丰富的人群中简化使用比克替拉韦/恩曲他滨/丙酚替诺福韦 José L Casado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3242–3247, 7 Effects of commonly used antibiotics on children’s developing gut microbiomes and resistomes in peri-urban Lima, Peru 秘鲁利马市郊常用抗生素对儿童发育中的肠道微生物组和耐药组的影响 Neha Sehgal and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3248–3256, 8 Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study 衰弱指数实验室（FI-Lab）作为预测院内多重耐药肺炎克雷伯菌血流感染不良预后的指标：一项单中心回顾性队列研究 Carmen Pellegrino and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3257–3264, 9 Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes 体外衍生的产OXA-48样酶肺炎克雷伯菌突变体对头孢他啶/阿维巴坦的耐药机制 T Blanco-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3265–3272, 10 Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales 肠杆菌目中氨曲南/阿维巴坦药敏试验的纸片扩散法和肉汤微量稀释法的比较评价 Ioannis Baltas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3273–3277, 11 Efficacy of topical hydrophilic gel of paromomycin combined with systemic or locally administered leishmanicidal drugs for treatment of experimental leishmaniasis caused by Leishmania (Viannia) braziliensis 硫酸巴龙霉素亲水性凝胶局部用药联合全身或局部使用杀利什曼原虫药物治疗巴西利什曼原虫（Viannia亚属）引起的实验性利什曼病的疗效 Líndicy Leidicy Alves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3278–3287, 12 Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies 血液系统恶性肿瘤患儿中头孢噻利的群体药代动力学及剂量优化 Jing-Rui Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3288–3296, 13 Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol 治疗产超广谱β-内酰胺酶（ESBL）和/或AmpC酶且不产碳青霉烯酶的肠杆菌目细菌的挑战：新型β-内酰胺/β-内酰胺酶抑制剂组合和头孢地尔的体外评价 Inès Rezzoug and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3297–3305, 14 Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study 使用多西环素进行暴露后预防（DoxyPEP）以在现实环境中预防性传播感染：PRIDOX研究 R Palacios and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3306–3310, 15 Risk–benefit balance of blood cultures among patients with stage IV cancer in unplanned admission: a nationwide propensity score–weighted study in Japan 日本全国范围内倾向评分加权研究：IV期癌症患者非计划入院时血培养的风险-获益平衡 Yuki Hashimoto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3311–3319, 16 A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma 对美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准的药物进行药物再利用筛选，发现两种对真性着色真菌病有活性的NF-κB抑制剂 Jingyi Ma and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3320–3328, 17 Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study 替莫西林与其他静脉注射β-内酰胺类药物治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究 Jeanne Iachkine and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3329–3334, 18 Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections 感染科医生对碳青霉烯耐药肠杆菌目感染的治疗偏好 Samuel E Cincotta and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3335–3339, 19 The aphA1 kanamycin and neomycin resistance gene originated in Klebsiella michiganensis aphA1卡那霉素和新霉素耐药基因起源于密歇根克雷伯菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3340–3344, 20 Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance 头孢他啶-阿维巴坦耐药且不产碳青霉烯酶的碳青霉烯耐药肠杆菌目的全球易感性特征和潜在耐药机制：2020-2023年来自抗菌药物测试领导与监测的数据 Chih-Cheng Lai and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3345–3351, 21 Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa 头孢他啶-阿维巴坦联合氨曲南与固定组合氨曲南/阿维巴坦对多重耐药铜绿假单胞菌的体外活性比较 Sophie E Müller and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3352–3356, 22 Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes 粪肠球菌中双重β-内酰胺协同作用及其与青霉素-头孢曲松感染性心内膜炎治疗结果的关系 April Gregson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3357–3366, 23 The long walk to a short half-life: the discovery of augmented renal clearance and its impact on antibiotic dosing 走向短半衰期的漫长之路：发现肾增强清除及其对抗菌药物剂量调整的影响 Jeffrey Lipman and Russell E Lewis Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3367–3374, 24 Aztreonam-amoxicillin/clavulanate combination therapy against blaNDM-producing Enterobacterales infections 氨曲南-阿莫西林/克拉维酸联合治疗产blaNDM肠杆菌目感染 Efrat Orenbuch-Harroch and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3375–3380, 25 Evaluation of sodium zirconium cyclosilicate usage for hyperkalaemia secondary to sulfamethoxazole/trimethoprim therapy 评估锆酸钠环硅酸盐用于磺胺甲恶唑/甲氧苄啶治疗继发的高钾血症 Dixie Pyles and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3381–3385, 26 Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis 每周三次血液透析后使用头孢他啶可在类鼻疽患者中达到足够的透析前浓度并实现临床治愈 Simon Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3386–3390, 27 In vitro and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent 体外和临床数据表明，新型吸入抗真菌药物奥培康唑的药物-药物相互作用风险可忽略不计 Lindsey M R Cass and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3391–3400, 28 Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial 在ALLG AMLM16试验中，FLT3-ITD阳性急性髓系白血病患者在初始诱导和巩固治疗期间接受索拉非尼治疗时的抗真菌预防 Chin Fen Neoh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3401–3406, 29 The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections 基于替加环素的联合用药对多重耐药鲍曼不动杆菌引起的血流感染的协同活性 Huan Zhang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3407–3418, 30 Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage? 儿科患者中哌拉西林的剂量调整与肾增强清除：现行指南是否足以达到治疗浓度覆盖？ Anne Ravix and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3419–3430, 31 Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model 在中性粒细胞减少的小鼠大腿感染模型中评估人模拟氨曲南-阿维巴坦对嗜麦芽窄食单胞菌的疗效 Yakun Fu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3431–3437, 32 A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study) 西班牙HIV感染者长期使用卡博特韦和利匹韦林的有效性和持久性的前瞻性评估（RELATIVITY研究） Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3438–3451, 33 Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus 奥洛罗芬和伏立康唑对烟曲霉的体外拮抗作用 Illan Laloum and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3452–3461, RESEARCH LETTERS（研究快讯） 34 Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury 静脉注射万古霉素联用导致大剂量甲氨蝶呤清除延迟和急性肾损伤 Thao Dao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3462–3464, 35 Overestimation of piperacillin/tazobactam resistance in Escherichia coli by disc diffusion and gradient strip methods 纸片扩散法和梯度条法高估大肠埃希菌对哌拉西林/他唑巴坦的耐药性 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3464–3467, 36 Mind the gap: missed re-initiation and monitoring in statin–antimicrobial co-prescriptions 注意差距：他汀类药物与抗菌药物联合处方中的漏重新起始和监测 Melwin Kyle Solis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3467–3468, 37 Pharmacokinetics of aztreonam/avibactam in a critically ill patient with a class B metallo-β-lactamase producing Enterobacteriaceae and receiving continuous renal replacement therapy 一名接受连续肾脏替代治疗且感染产B类金属β-内酰胺酶肠杆菌科细菌的重症患者中氨曲南/阿维巴坦的药代动力学 Daniel Fresán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3469–3471, CORRECTION（更正） 38 Correction to: Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 更正：系统评价与《抗菌药物化疗杂志》：过去、现在和未来。一项系统再评价 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3472–3473,

100 项与利福平相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00211	利福平	J04AB02	DB01045

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
细胞内鸟分枝杆菌感染	日本	Daiichi Sankyo Co., Ltd.	2011-05-20
非结核分枝杆菌感染	日本	Daiichi Sankyo Co., Ltd.	2011-05-20
嗜血杆菌感染	澳大利亚	Sanofi-Aventis Australia Pty Ltd.	2009-01-21
脑膜炎球菌感染	美国	Sanofi-Aventis U.S. LLC	1989-05-25
麻风	中国	四川省长征药业股份有限公司	1981-01-01
麻风	中国	茂祥集团吉林制药有限公司	1981-01-01
麻风	中国	成都通德药业有限公司	1981-01-01
麻风	中国	国药控股股份有限公司	1981-01-01
麻风	中国	成都第一制药有限公司	1981-01-01
麻风	中国	四川彩虹制药有限公司	1981-01-01
结核	中国	成都通德药业有限公司	1981-01-01
结核	中国	成都第一制药有限公司	1981-01-01
结核	中国	四川彩虹制药有限公司	1981-01-01
结核	中国	国药控股股份有限公司	1981-01-01
结核	中国	茂祥集团吉林制药有限公司	1981-01-01
结核	中国	四川省长征药业股份有限公司	1981-01-01
脑膜炎	美国	Oxford Pharmaceuticals LLC	1971-05-21
肺结核	美国	Oxford Pharmaceuticals LLC	1971-05-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
假体关节感染	临床3期	法国	Sanofi	2009-04-01
多发性硬化症	临床1期	美国	Sanofi	2020-05-18
自身免疫性疾病	临床1期	英国	Kadmon Corp. LLC	2018-04-09
糖尿病	临床1期	法国	Sanofi	2017-02-27
肥胖	临床前	中国	北京协和医学院	2025-07-01
肥胖	临床前	中国	中国医学科学院	2025-07-01
额颞痴呆	临床前	美国	medilabo RFP, Inc.	2023-03-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06041919 (CTgov)	临床2期	肺结核	20	RESP301 (1 (Active))	鑰窪膚齋鹹遞襯積艱觸(膚憲築窪鬱願醖鬱艱鬱) = 憲願獵艱選鏇膚膚繭齋觸夢網選艱衊鑰積膚繭 (構選積淵醖鏇鬱築築構, 網獵壓築築鹽獵衊憲鬱 ~ 簾窪鏇膚衊積製窪築蓋) 更多	-	2025-07-15
				ethambutol+rifampicin+isoniazid+pyrazinamide (2 (Control))	鑰窪膚齋鹹遞襯積艱觸(膚憲築窪鬱願醖鬱艱鬱) = 鬱鏇廠網憲齋艱鑰網齋觸夢網選艱衊鑰積膚繭 (構選積淵醖鏇鬱築築構, 簾窪蓋齋膚製鑰網網憲 ~ 窪選構積築襯鏇蓋艱壓) 更多
NCT03474198 (TRUNCATE-TB, Pubmed \| Lancet Infect Dis)	临床2/3期	肺结核	675	Standard Treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol)	憲觸願鏇廠糧鹹顧積網(廠蓋窪範範構壓淵鹹獵) = 簾鬱憲衊壓糧觸鏇襯夢衊壓醖鹹範夢糧製觸夢 (餘鑰選簾膚淵願鏇淵願 ) 更多	不佳	2025-05-01
				High-dose rifampicin and linezolid	憲觸願鏇廠糧鹹顧積網(廠蓋窪範範構壓淵鹹獵) = 獵鑰鹹選齋鑰範膚製鏇衊壓醖鹹範夢糧製觸夢 (餘鑰選簾膚淵願鏇淵願 ) 更多
NCT05592223 (CTgov)	临床1期	结核	20	BCG Vaccine USP+Isoniazid (BCG Challenged-Isoniazid Treated)	製襯繭艱構築膚積蓋艱(窪鬱積鑰構鑰顧觸繭繭) = 鏇廠夢選鏇構築淵憲築蓋衊蓋餘壓壓窪鏇積蓋 (鹽築襯鑰壓糧鬱觸構遞, 40,516) 更多	-	2025-03-25
				BCG Vaccine USP (BCG Challenged-Isoniazid Untreated)	製襯繭艱構築膚積蓋艱(窪鬱積鑰構鑰顧觸繭繭) = 窪願製艱選範廠廠艱選蓋衊蓋餘壓壓窪鏇積蓋 (鹽築襯鑰壓糧鬱觸構遞, 92) 更多
NCT03662022 (PEOPLE, CTgov)	临床3期	麻风	144,000	PEP (no PEP)	憲網範窪顧憲鬱願衊鏇 = 襯範憲夢齋鑰夢簾鏇淵襯醖壓鑰窪糧鬱鏇鏇壓 (顧廠獵簾構淵選衊顧鏇, 遞觸衊窪網範壓淵鹹範 ~ 淵淵鏇壓顧積獵淵願襯)	-	2025-03-04
				Rifampicin (Household PEP)	憲網範窪顧憲鬱願衊鏇 = 鹹遞願壓齋築網選鏇淵襯醖壓鑰窪糧鬱鏇鏇壓 (顧廠獵簾構淵選衊顧鏇, 蓋襯顧憲觸鬱網艱鬱壓 ~ 窪鏇製遞積夢網鏇鏇醖) 更多
NCT05364671 (CTgov)	临床3期	新型冠状病毒感染	771	Raphamin (Raphamin)	糧憲遞構鏇鬱淵蓋醖構 = 築願範醖簾糧襯襯顧顧餘淵築鬱觸顧淵製願夢 (蓋獵鬱顧膚齋網觸艱選, 鹹觸網繭遞醖餘鹽齋壓 ~ 壓構觸蓋餘顧觸願獵餘) 更多	-	2025-01-06
				Placebo (Placebo)	糧憲遞構鏇鬱淵蓋醖構 = 鏇構鑰廠簾簾憲鑰蓋鬱餘淵築鬱觸顧淵製願夢 (蓋獵鬱顧膚齋網觸艱選, 範積廠選鹹糧夢淵衊醖 ~ 鹹築製鏇顧淵願製構範) 更多
NCT04918771 (CTgov)	临床3期	病毒性呼吸道感染	435	Raphamin (Raphamin)	選選襯積獵齋願壓願範(鹹壓構築網遞鏇淵顧衊) = 廠壓簾願製選繭窪鹽鬱遞醖積築衊構鑰積齋積 (蓋醖淵觸壓顧鑰觸築願, 1.7) 更多	-	2024-10-15
				Placebo (Placebo)	選選襯積獵齋願壓願範(鹹壓構築網遞鏇淵顧衊) = 顧艱夢選構製齋廠夢獵遞醖積築衊構鑰積齋積 (蓋醖淵觸壓顧鑰觸築願, 2.6) 更多
NCT04021121 (ALTER, CTgov)	临床2期	脑膜结核	40	High dose RIF+LZD (High Dose RIF With LZD)	醖鑰繭夢醖壓餘選簾醖(淵選鏇廠艱繭齋築艱顧) = 壓鏇壓鑰網齋鏇壓淵醖構構鏇夢願憲蓋艱淵遞 (範糧糧簾糧鏇窪憲網遞, 蓋觸築蓋選襯憲鏇選糧 ~ 膚憲鏇齋繭獵餘蓋積積) 更多	-	2024-10-01
				Standard dose RIF+LZD (Standard Dose RIF With LZD)	醖鑰繭夢醖壓餘選簾醖(淵選鏇廠艱繭齋築艱顧) = 願築蓋窪醖製餘齋壓鏇構構鏇夢願憲蓋艱淵遞 (範糧糧簾糧鏇窪憲網遞, 鑰鹹餘艱願遞膚糧衊願 ~ 鹹壓淵選廠鬱願構衊積) 更多
NCT04485156 (Pubmed \| Tuberc Respir Dis (Seoul)) 人工标引	临床3期	肺结核	58	rifampicinrisoniazid,pyrazinamideand pyrazinamide	選艱糧齋餘顧憲選鬱夢(鑰膚廠夢淵獵蓋窪鑰築) = 膚繭艱膚膚衊憲襯遞製餘壓夢齋壓襯願蓋製齋 (壓壓膚鏇壓淵構夢繭鬱 )	不佳	2024-09-27
				Standard 6-month regimen	選艱糧齋餘顧憲選鬱夢(鑰膚廠夢淵獵蓋窪鑰築) = 蓋鹹範築獵夢夢憲範憲餘壓夢齋壓襯願蓋製齋 (壓壓膚鏇壓淵構夢繭鬱 )
NCT03988933 (Pubmed) 人工标引	临床2期	结核一线	1,368	rifampicinose group (10 mg/kg once daily for 4 months)	糧鏇壓窪夢窪遞糧鑰憲(膚願網壓製醖遞製選壓) = 糧觸衊窪襯遞衊鹹繭蓋選壓襯積顧憲艱遞遞膚 (糧積淵淵醖鹹網齋簾簾 )	不佳	2024-03-26
				rifampicinroup (20 mg/kg daily for 2 months)	糧鏇壓窪夢窪遞糧鑰憲(膚願網壓製醖遞製選壓) = 淵衊鑰艱襯選廠製製簾選壓襯積顧憲艱遞遞膚 (糧積淵淵醖鹹網齋簾簾 )
NCT04525235 (Pubmed \| Antimicrob Agents Chemother)	临床1期	肺结核	25	RIF40	製蓋製齋蓋鏇範襯廠衊(鹽獵糧齋鹽鑰範積築網) = 淵鏇鑰築選餘願艱齋網顧衊膚積鹹蓋構觸醖願 (築壓網夢鬱繭網蓋獵鑰, 96 ~ 115) 更多	积极	2023-10-18